Sales Rep Wants Docs Public In $40B Celgene FCA Row
Celgene Corp. hasn't proven that documents it wants to seal in a $40 billion False Claims Act suit over off-label promotion of the cancer drugs Thalomid and Revlimid would be harmful...To view the full article, register now.
Already a subscriber? Click here to view full article